Cecilia Brown

DocwireNews

The US Food and Drug Administration has approved durvalumab (Imfinzi, AstraZeneca) with platinum-containing chemotherapy as neoadjuvant treatment, followed by single-agent durvalumab as adjuvant treatment after surgery for adults with resectable tumors &ge;4 cm and/or node-positive non-small cell lung cancer (NSCLC) and no known EGFR mutations or ALK rearrangements.The efficacy and safety of the treatment was evaluated in the AEGEAN trial, which was a randomized, double-blind, placebo-controlled multicenter trial. The trial evaluated the treatment in 802 patients with previously untreated and resectable squamous or nonsquamous NSCLC in stage IIA to select stage IIIB. The AEGEAN trial investigators randomized patients 1:1 to receive neoadjuvant treatment with durvalumab or placebo with platinum-based chemotherapy every 3 weeks for up to 4 cycles. This was followed by adjuvant treatment with continued single-agent durvalumab or placebo every 4 weeks for up to 12 cycles.The major efficacy outcome measures were event-free survival (EFS) by blinded independent central review assessment and pathological complete response (pCR) by blinded central pathology review.The study showed that the median EFS was not reached (95% CI, 31.9 months to not estimable) in the durvalumab arm and 25.9 months (95% CI, 18.9 months to not estimable) in the placebo arm (hazard ratio, 0.68; 95% CI, 0.53-0.88; P=.0039).The pCR rate was 17.0% in patients receiving durvalumab, compared with 4.3% in the patients receiving placebo.&ldquo;At the time of the prespecified interim analyses, overall survival was not formally tested for statistical significance; however, a descriptive analysis revealed no clear detriment,&rdquo; FDA officials said in a news release announcing the approval.Anemia, nausea, constipation, fatigue, musculoskeletal pain, and rash were the most common adverse events reported. Among the patients receiving neoadjuvant durvalumab, 1.7% were unable to receive surgery due to adverse reactions. The rate was 1% in the patients who were receiving placebo.For patients with a body weight of &ge;30 kg, the recommended neoadjuvant dose of durvalumab is 1500 mg every 3 weeks and every 4 weeks for adjuvant treatment, according to the FDA. For patients with a body weight of &lt;30 kg, the recommended durvalumab dosage is 20 mg/kg. Durvalumab should be administered prior to chemotherapy when administered on the same day.Source: <a href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neoadjuvantadjuvant-durvalumab-resectable-non-small-cell-lung-cancer">FDA </a>

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

FDA Approves Neoadjuvant, Adjuvant Durvalumab for Resectable NSCLC

Non-Small Cell Lung Cancer

The US FDA has approved durvalumab (Imfinzi, AstraZeneca) with platinum-containing chemotherapy as neoadjuvant treatment, followed by durvalumab, for certain adults with NSCLC.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe